__25J148Qli3.jpg)
我們使用 Cookie 以允許我們網站的正常工作、個性化設計內容和廣告、提供社交媒體功能並分析流量。我們還同社交媒體、廣告和分析合作夥伴分享有關您使用我們網站的信息
16
Oct 2025
Latest News
ScinoPharm Taiwan Hosts Healing Art Forum in Partnership with Formosa Cancer Foundation
ScinoPharm Taiwan recently held its 16th annual ScinoPharm Art Forum, a long-standing public art and cultural lecture series dedicated to enriching lives through art and dialogue.
Read More
19
Dec 2024
Latest News
ScinoPharm Partners with Handa Pharmaceuticals to Advance 505(b)(2) Drug Development
ScinoPharm Taiwan, Ltd. today announced a strategic investment in Handa Pharmaceuticals, Inc., marking the beginning of a collaboration to share R&D resources and leverage complementary strengths in advancing 505(b)(2) new drug development. This partnership will drive efforts in research, clinical trials, regulatory approvals, and product commercialization.
Read More
20
Nov 2024
Latest News
ScinoPharm Taiwan Achieves Zero-Deficiency Record in ANVISA Inspection, Expanding Its Presence in Emerging Markets
ScinoPharm Taiwan (SPT) (stock code 1789) has not only solidified its position in the US and EU pharmaceutical markets, but is continuing to extend its reach into promising emerging markets, demonstrating its commitment to expand its global footprint.
Read More
13
Aug 2024
Latest News
ScinoPharm Taiwan H1 performance strong, expands focus on injectable and CDMO businesses
ScinoPharm Taiwan (stock code 1789) reported consolidated revenue of NT$1.646 billion for the first half of 2024, with a post-tax net profit of NT$215 million, representing a 117% increase compared to the same period last year.
Read More
06
May 2024
Latest News
ScinoPharm Taiwan Reports 36% YoY Revenue Growth in Q1; Both Injectable Plant and China Subsidiary Pass US FDA Inspection with Zero Deficiencies
ScinoPharm Taiwan (stock code 1789) announced today that its consolidated revenue for the first quarter reached NT$883 million, representing an increase of 36.21% compared to the same period last year. The sales momentum remained robust in the first quarter of 2024, resulting in increased shipments. And The first quarter consolidated net profit reached NT$140 million, marking a remarkable growth of 233% compared to the same period last year.
Read More